• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管活性肠肽受体1(VPAC1)过表达与结肠癌的低分化相关。

VPAC1 overexpression is associated with poor differentiation in colon cancer.

作者信息

Liu Shaohua, Zeng Yunjie, Li Yunhua, Guo Wenying, Liu Jiali, Ouyang Nengtai

机构信息

The laboratory of Surgery, Pingxiang Health School, Pingxiang, Jiangxi province, China.

出版信息

Tumour Biol. 2014 Jul;35(7):6397-404. doi: 10.1007/s13277-014-1852-x. Epub 2014 Mar 28.

DOI:10.1007/s13277-014-1852-x
PMID:24671823
Abstract

Vasoactive intestinal peptide (VIP) is a neurotransmitter that primarily functions as a vasodilator. VIP plays its role through binding to its receptors known as VIP/pituitary adenylate cyclase-activating peptide receptors (VPACs). In this study, we examined the expression of VPAC1 in human colon cancer tissues, analyzed the relationship between VPAC1 expression and cancer malignancy, and explored the possible mechanisms using immunohistochemistry and immunofluorescence double staining. The results showed that (1) poorly differentiated colon cancers have significantly higher VPAC1 expression than well-differentiated colon cancers do (p < 0.01); (2) phospho-epithelial growth factor receptor (EGFR) overexpression/activation in the cytoplasm of cancer cells is related to VPAC1 overexpression; (3) blood vessels surrounding colon cancer have significantly more VPAC1-positive than normal colon mucosa does; (4) tumor-associated macrophages (TAMs) of colon cancer have a higher level of VPAC1 expression than macrophages in normal colon mucosa do. These data suggest that VPAC1 overexpression is associated with poorer differentiation of colon cancer, which is likely caused by subsequent EGFR activation in cancer cells. In addition, VPAC1 overexpression in both blood vessels and macrophages in tumors may also play an important role in the development of aggressive cancer.

摘要

血管活性肠肽(VIP)是一种主要作为血管舒张剂起作用的神经递质。VIP通过与称为VIP/垂体腺苷酸环化酶激活肽受体(VPACs)的受体结合来发挥其作用。在本研究中,我们使用免疫组织化学和免疫荧光双重染色检查了人结肠癌组织中VPAC1的表达,分析了VPAC1表达与癌症恶性程度之间的关系,并探讨了可能的机制。结果表明:(1)低分化结肠癌的VPAC1表达明显高于高分化结肠癌(p<0.01);(2)癌细胞胞质中磷酸化表皮生长因子受体(EGFR)的过表达/激活与VPAC1的过表达有关;(3)结肠癌周围血管的VPAC1阳性表达明显多于正常结肠黏膜;(4)结肠癌的肿瘤相关巨噬细胞(TAM)中VPAC1的表达水平高于正常结肠黏膜中的巨噬细胞。这些数据表明,VPAC1过表达与结肠癌的低分化有关,这可能是由癌细胞随后的EGFR激活引起的。此外,肿瘤血管和巨噬细胞中VPAC1的过表达也可能在侵袭性癌症的发展中起重要作用。

相似文献

1
VPAC1 overexpression is associated with poor differentiation in colon cancer.血管活性肠肽受体1(VPAC1)过表达与结肠癌的低分化相关。
Tumour Biol. 2014 Jul;35(7):6397-404. doi: 10.1007/s13277-014-1852-x. Epub 2014 Mar 28.
2
Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.血管活性肠肽主要受体VPAC1在肠道全长中的表达及定位
Am J Physiol Gastrointest Liver Physiol. 2017 Jul 1;313(1):G16-G25. doi: 10.1152/ajpgi.00081.2017. Epub 2017 Apr 6.
3
The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.人血管活性肠肽/垂体腺苷酸环化酶激活肽受体1(VPAC1)启动子:在结肠癌细胞系Caco-2Cl.20肠细胞分化过程中对受体表达的特征及作用
Biochem J. 2000 May 1;347 Pt 3(Pt 3):623-32.
4
A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.克隆的蛙血管活性肠肽/垂体腺苷酸环化酶激活肽受体具有哺乳动物中VPAC1和VPAC2受体的药理学及组织分布特征。
Endocrinology. 1999 Mar;140(3):1285-93. doi: 10.1210/endo.140.3.6576.
5
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.人肿瘤及其起源组织中的血管活性肠肽/垂体腺苷酸环化酶激活肽受体亚型
Cancer Res. 2000 Jun 1;60(11):3105-12.
6
Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.垂体腺苷酸环化酶激活多肽、血管活性肠肽及其受体在小鼠卵巢中的表达定位与功能活性
Reproduction. 2007 Aug;134(2):281-92. doi: 10.1530/REP-07-0051.
7
Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis.肠黏膜肥大细胞中 VPAC1 的上调与血管活性肠肽在炎症性肠病和小鼠结肠炎中的密切关系。
Neurogastroenterol Motil. 2019 Mar;31(3):e13503. doi: 10.1111/nmo.13503. Epub 2018 Nov 8.
8
Epithelial expression of vasoactive intestinal peptide in ulcerative colitis: down-regulation in markedly inflamed colon.溃疡性结肠炎中血管活性肠肽的上皮表达:在明显炎症的结肠中下调。
Dig Dis Sci. 2012 Feb;57(2):303-10. doi: 10.1007/s10620-011-1985-3. Epub 2011 Dec 6.
9
Gene expression of vasoactive intestinal peptide receptors in human lung cancer.血管活性肠肽受体在人肺癌中的基因表达。
Int J Oncol. 2011 Oct;39(4):1019-24. doi: 10.3892/ijo.2011.1122. Epub 2011 Jul 13.
10
Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.VPAC1 和 VPAC2 在 VIP 介导的大鼠肺动脉和主动脉平滑肌细胞增殖抑制中的作用。
Peptides. 2010 Aug;31(8):1517-22. doi: 10.1016/j.peptides.2010.04.024. Epub 2010 May 7.

引用本文的文献

1
Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization.肝素寡糖通过其结合过程的表征作为血管活性肠肽抑制剂。
Curr Protein Pept Sci. 2024;25(6):480-491. doi: 10.2174/0113892037287189240122110819.
2
Identification of the Diagnostic Biomarker VIPR1 in Hepatocellular Carcinoma Based on Machine Learning Algorithm.基于机器学习算法的肝细胞癌诊断生物标志物血管活性肠肽受体1的鉴定
J Oncol. 2022 Sep 15;2022:2469592. doi: 10.1155/2022/2469592. eCollection 2022.
3
[VIPR1 promoter methylation promotes transcription factor AP-2 binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth ].

本文引用的文献

1
Cellular functions regulated by phosphorylation of EGFR on Tyr845.由表皮生长因子受体(EGFR)酪氨酸845位点磷酸化所调控的细胞功能。
Int J Mol Sci. 2013 May 23;14(6):10761-90. doi: 10.3390/ijms140610761.
2
Effect of VIP on intracellular [Ca2+], extracellular regulated kinase 1/2, and secretion in cultured rat conjunctival goblet cells.VIP 对培养的大鼠结膜杯状细胞细胞内 [Ca2+]、细胞外调节激酶 1/2 和分泌的影响。
Invest Ophthalmol Vis Sci. 2013 Apr 23;54(4):2872-84. doi: 10.1167/iovs.12-11264.
3
VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.
血管活性肠肽受体1(VIPR1)启动子甲基化促进转录因子AP-2结合,抑制VIPR1表达并促进肝癌细胞生长
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jul 20;42(7):957-965. doi: 10.12122/j.issn.1673-4254.2022.07.01.
4
Systematically integrative analysis identifies diagnostic and prognostic candidates and small-molecule drugs for lung adenocarcinoma.系统性综合分析确定了肺腺癌的诊断和预后候选指标以及小分子药物。
Transl Cancer Res. 2021 Aug;10(8):3619-3646. doi: 10.21037/tcr-21-526.
5
Obesity-related gut hormones and cancer: novel insight into the pathophysiology.肥胖相关肠道激素与癌症:病理生理学的新见解。
Int J Obes (Lond). 2021 Sep;45(9):1886-1898. doi: 10.1038/s41366-021-00865-8. Epub 2021 Jun 4.
6
Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression.粪便样本中结直肠癌的早期检测——追踪影响基因表达的 CpG 岛甲基化改变。
Int J Mol Sci. 2020 Jun 24;21(12):4494. doi: 10.3390/ijms21124494.
7
The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management.神经肽系统与结直肠癌肝转移:机制与治疗。
Int J Mol Sci. 2020 May 15;21(10):3494. doi: 10.3390/ijms21103494.
8
Colorectal Cancer Invasion and Atrophy of the Enteric Nervous System: Potential Feedback and Impact on Cancer Progression.结直肠癌对肠神经系统的侵袭和萎缩:潜在的反馈及对癌症进展的影响。
Int J Mol Sci. 2020 May 11;21(9):3391. doi: 10.3390/ijms21093391.
9
Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells.VIPR1 基因调控人肺腺癌细胞 H1299 的机制。
Med Oncol. 2019 Sep 27;36(11):91. doi: 10.1007/s12032-019-1312-y.
10
Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system.血管活性肠肽生理与病理生理学的最新进展:聚焦于胃肠系统
F1000Res. 2019 Sep 12;8. doi: 10.12688/f1000research.18039.1. eCollection 2019.
VIP 和 PACAP:CNS 炎症、损伤和修复的神经肽调节剂。
Br J Pharmacol. 2013 Jun;169(3):512-23. doi: 10.1111/bph.12181.
4
VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium.大鼠脑动脉中的 VIP/PACAP 受体:特征、定位及与细胞内钙的关系。
Neuropeptides. 2013 Apr;47(2):85-92. doi: 10.1016/j.npep.2012.12.005. Epub 2013 Feb 1.
5
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.血管活性肠肽受体和环氧化酶-2 在人前列腺癌中的过表达。分析潜在的预后相关性。
Histol Histopathol. 2012 Aug;27(8):1093-101. doi: 10.14670/HH-27.1093.
6
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.RNA 干扰靶向沉默 VPAC1 受体抑制 VIP 对人乳腺癌细胞中 EGFR 和 HER2 转导激活以及 VEGF 分泌的作用。
Mol Cell Endocrinol. 2012 Jan 2;348(1):241-6. doi: 10.1016/j.mce.2011.08.031. Epub 2011 Aug 27.
7
VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.血管活性肠肽(VIP)受体 1(VPAC1)G 蛋白偶联受体介导 VIP 增强实验性结肠炎的作用。
Cell Immunol. 2011;267(2):124-32. doi: 10.1016/j.cellimm.2011.01.001. Epub 2011 Jan 7.
8
Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells.PACAP 和 VIP 对高血糖诱导的小鼠微血管内皮细胞增殖的影响。
Peptides. 2010 Dec;31(12):2276-83. doi: 10.1016/j.peptides.2010.08.013. Epub 2010 Aug 26.
9
Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. toll 样受体刺激对巨噬细胞中血管活性肠肽 2 型受体的调节作用具有差异性。
J Cell Mol Med. 2009 Sep;13(9B):3209-17. doi: 10.1111/j.1582-4934.2009.00662.x.
10
Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.慢性阻塞性肺疾病患者来源的单核细胞衍生巨噬细胞中血管活性肠肽(VIP)受体的表达。
Peptides. 2010 Apr;31(4):603-8. doi: 10.1016/j.peptides.2009.12.014. Epub 2009 Dec 22.